Donepezil Hydrochloride Tablet, Orally Disintegrating
Product Images NDC 29300-251

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 29300-251). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 01

Chemical structure of donepezil hydrochloride, showing its molecular framework with methoxy groups, a piperidine ring, and a benzyl moiety, including the hydrochloride (HCl) salt.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 02

A line graph showing the mean change from baseline in ADAS-cog scores over 24 weeks of drug treatment comparing donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis measures cognitive change, with clinical improvement indicated upwards and clinical decline downwards. Both donepezil doses show cognitive improvement relative to baseline, while placebo results in decline.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 03

A cumulative percentage graph showing the change from baseline in ADAS-cog scores for three treatment groups: Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis represents change from baseline, and the y-axis represents the cumulative percentage of patients. A table beside the graph lists the percentage of patients experiencing specific changes at -7, -4 points, and no change.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 04

A bar graph comparing treatment effects for donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo groups based on CIBIC-plus ratings. The x-axis shows categories from Markedly Improved to Markedly Worse, and the y-axis shows percentage of patients, illustrating distribution of patient outcomes for each treatment group.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 05

Line graph depicting the ADAS-cog score changes from baseline over 12 weeks of drug treatment with donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo, followed by a placebo period. The vertical axis shows clinical improvement and decline, while the horizontal axis represents weeks. Data points include mean changes and standard error bars for each treatment group.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 06

A cumulative percentage of patients line graph showing change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph compares three groups: donepezil hydrochloride 10 mg/day, donepezil hydrochloride 5 mg/day, and placebo. Points indicate specific changes from baseline of -7, -4, and no change, with a data table summarizing the percentage of patients in each group experiencing these changes in ADAS-cog scores.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 07

A bar chart comparing the percentages of patients across different CIBIC-plus rating categories for donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo groups. Categories range from Markedly Improved to Markedly Worse, illustrating patient response distribution by treatment type.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 08

A line chart showing clinical study results comparing the effect of donepezil hydrochloride 10 mg/day versus placebo on SIB change from baseline over 0, 3, and 6 months of drug treatment. The vertical axis represents mean SIB change with standard error. Donepezil shows clinical improvement, while placebo shows decline over time.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 09

A cumulative percentage of patients chart comparing the change from baseline SIB scores for Donepezil Hydrochloride 10 mg/day and placebo. The x-axis measures SIB change from baseline ranging from approximately -75 to 30, and the y-axis shows the cumulative percentage of patients from 0 to 100%. The donepezil group shows a steeper curve indicating greater change compared to placebo.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 10

This chart shows the change from baseline in ADCS-ADL scores over 6 months comparing donepezil hydrochloride 10 mg/day and placebo. The x-axis represents months of drug treatment (0, 3, 6), and the y-axis shows mean change from baseline with error bars. The chart indicates clinical improvement above baseline and clinical decline below it.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 11

A line graph showing the cumulative percentage of patients versus ADCS-ADL change from baseline. It compares Donepezil Hydrochloride 10mg/day with placebo, depicting patient response distribution over changes in ADCS-ADL scores.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 12

A line graph illustrating the change in SIB (Severe Impairment Battery) scores from baseline over 24 weeks of treatment with donepezil hydrochloride at daily doses of 23 mg and 10 mg. The x-axis represents weeks of drug treatment, and the y-axis represents LS mean change from baseline with standard error. The 23 mg dose shows a greater improvement over time compared to the 10 mg dose.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 13

A cumulative percentage graph showing patients' SIB (Severe Impairment Battery) change from baseline for donepezil hydrochloride at doses of 10 mg/day and 23 mg/day. The x-axis shows SIB change ranging from +50 to -60, and the y-axis shows cumulative percentage of patients from 0 to 100%. Two curves illustrate response distribution for each dose group.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 14

Bar chart comparing the percentage of patients by CIBIC-plus rating categories for donepezil hydrochloride 23 mg/day and 10 mg/day. Categories range from markedly improved to markedly worse, showing a higher percentage of no change in both groups, with detailed distribution across various improvement and worsening levels.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 15

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 16

Donepezil Hydrochloride 5 mg tablets, USP, film-coated oral tablets. The label specifies 30 tablets per container and is marked Rx Only. Manufactured by Unichem Laboratories Ltd., India, and for Unichem Pharmaceuticals (USA), Inc., East Brunswick, NJ. Storage instructions and dosage guidance to refer to package insert are included.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 17

Label for donepezil hydrochloride tablets USP 10 mg by Unichem Pharmaceuticals (USA), Inc. The film-coated oral tablets come in a bottle containing 30 tablets. The label includes storage instructions (20° to 25°C), usage notes to see the package insert, and manufacturer information for Unichem Laboratories Ltd. in India and Unichem Pharmaceuticals (USA), Inc. in New Jersey.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 18

Donepezil Hydrochloride 5 mg orally disintegrating tablets carton label showing the product name, dosage strength, and form. The label indicates 30 tablets in 3 x 10 unit-dose blisters. Manufactured by Unichem Laboratories Ltd. in India and labeled for Unichem Pharmaceuticals (USA), Inc. The label includes a barcode, storage instructions, and a warning to keep out of reach of children.*

FDA Label Image

C40f39a9 434c 41f3 9258 Deb4a34457d3 19

Donepezil Hydrochloride Orally Disintegrating Tablets USP 10 mg packaging label showing a carton design. The label includes the proprietary and generic names, strength (10 mg), dosage form (orally disintegrating tablets), quantity (30 tablets in 3 x 10 unit-dose blisters), and the manufacturer Unichem Laboratories Ltd. in India. It also shows the labeler Unichem Pharmaceuticals (USA), Inc., located in East Brunswick, NJ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.